UK-based pharmaceutical holding company Lansen Pharmaceutical Holdings plans to sell a 6.32% share in Zhejiang Starry Pharmaceutical.

The transaction will see Lansen Pharmaceutical selling no more than 7.5 million shares in the target company.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Based in China, the target company is involved in research and development (R&D), production and marketing of active ingredient and intermediate X-CT non-ionic contrast agent.

Fagron has agreed to purchase Humco Holding Group (Humco) for €56.9m ($70m).

Humco will receive €38.6m ($47.5m) in cash and another €18.3m ($22.5m) over a two-year period upon achieving performance-linked milestones.

Fagron will acquire all technologies, scientific data, patents and trademarks, and a production facility of Humco located in Texas, as part of the acquisition.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Fagron has agreed to purchase Humco Holding Group (Humco) for €56.9m ($70m).”

Based in Belgium, the acquirer company is a pharmaceutical compounding solutions provider, while the target company is a US-based company involved in the development of patented delivery vehicles and branded pharmaceutical products for pharmacies.

The acquisition will enable Fagron to reinforce its strategic position in the US.

Humco has appointed Jones Day as the legal advisor, while Morgan, Lewis & Bockius has been appointed as the legal advisor by Fagron.

Hunan Fangsheng Pharmaceutical has agreed to provide $3m to LipoMedics in exchange for a 35.95% interest.

Hunan is a pharmaceutical company based in China, while LipoMedics is a UK-based company involved in providing personalised paclitaxel therapy.